PT3576740T - Cancer treatment - Google Patents

Cancer treatment

Info

Publication number
PT3576740T
PT3576740T PT187022991T PT18702299T PT3576740T PT 3576740 T PT3576740 T PT 3576740T PT 187022991 T PT187022991 T PT 187022991T PT 18702299 T PT18702299 T PT 18702299T PT 3576740 T PT3576740 T PT 3576740T
Authority
PT
Portugal
Prior art keywords
cancer treatment
cancer
treatment
Prior art date
Application number
PT187022991T
Other languages
Portuguese (pt)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PT3576740T publication Critical patent/PT3576740T/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT187022991T 2017-12-20 2018-02-02 Cancer treatment PT3576740T (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17209098 2017-12-20

Publications (1)

Publication Number Publication Date
PT3576740T true PT3576740T (en) 2023-08-18

Family

ID=60702421

Family Applications (1)

Application Number Title Priority Date Filing Date
PT187022991T PT3576740T (en) 2017-12-20 2018-02-02 Cancer treatment

Country Status (5)

Country Link
EA (1) EA201991818A1 (en)
MA (1) MA47408B1 (en)
PT (1) PT3576740T (en)
TW (1) TWI798199B (en)
WO (1) WO2018141921A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3852756A1 (en) * 2018-09-21 2021-07-28 Janssen Pharmaceutica NV Treatment of cholangiocarcinoma
US20220041579A1 (en) * 2018-12-19 2022-02-10 Array Biopharma Inc. Substituted quinoxaline compounds as inhibitors of fgfr tyrosine kinases
BR112021015686A2 (en) * 2019-02-12 2021-10-26 Janssen Pharmaceutica N.V. CANCER TREATMENT
CA3133348A1 (en) * 2019-03-15 2020-09-24 Poly-Med, Inc. In situ gel-forming delivery systems, methods and compositions
CN113645975A (en) * 2019-03-29 2021-11-12 詹森药业有限公司 FGFR tyrosine kinase inhibitors for the treatment of urothelial cancer
AU2020282816A1 (en) * 2019-05-31 2022-01-06 Qed Therapeutics, Inc. Methods of treating urinary system cancers
CA3176713A1 (en) * 2019-12-09 2021-06-17 Cedars-Sinai Medical Center Use of fgfr inhibitors for treatment of idiopathic short stature
US20230110113A1 (en) * 2020-02-12 2023-04-13 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200201A1 (en) * 2015-02-10 2017-06-16 Astex Therapeutics Ltd Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine

Also Published As

Publication number Publication date
MA47408A (en) 2019-12-11
WO2018141921A1 (en) 2018-08-09
EA201991818A1 (en) 2020-02-05
MA47408B1 (en) 2023-08-31
TWI798199B (en) 2023-04-11
TW201839399A (en) 2018-11-01

Similar Documents

Publication Publication Date Title
IL271946A (en) Combination cancer therapy
HUE053191T2 (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
IL259996A (en) Combinations for the treatment of cancer
IL263802A (en) Cancer treatment combinations
HK1258319A1 (en) Cancer therapy
PT3576740T (en) Cancer treatment
IL263123A (en) Cancer treatments
HK1231561A1 (en) Cancer treatment
IL268463A (en) Cancer treatment
GB201706451D0 (en) Cancer treatment
HK1251794A1 (en) Cancer treatment
IL274626A (en) Cancer treatment
GB201707864D0 (en) Platinum-reistant cancer treatment
EP3576791A4 (en) Calreticulin-mediated cancer treatment
GB201704909D0 (en) Cancer therapy
GB201819920D0 (en) Cancer treatment
GB201711855D0 (en) Cancer therapy
GB201522433D0 (en) Cancer treatment
GB201713852D0 (en) Cancer treatment
GB201811431D0 (en) Cancer treatment
GB201804816D0 (en) Cancer treatment
GB201720533D0 (en) Cancer treatments
GB201711250D0 (en) Cancer therapy
GB201718806D0 (en) Breast cancer treatment
GB201710198D0 (en) Cancer therapy